Evidence map›Paper›PMID 37569332›Full record

ArticleInternational journal of molecular sciences2023

CD47 Expression in Circulating Tumor Cells and Circulating Tumor Microemboli from Non-Small Cell Lung Cancer Patients Is a Poor Prognosis Factor.

Jacqueline Aparecida Torres, Angelo Borsarelli Carvalho Brito, Virgilio Souza E Silva, Iara Monique Messias, Alexcia Camila Braun, Anna Paula Carreta Ruano, Marcilei E C Buim, Dirce Maria Carraro, Ludmilla Thomé Domingos Chinen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jacqueline Aparecida TorresInternational Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.ORCID 0000-0003-0253-3479
Angelo Borsarelli Carvalho BritoDepartment of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-900, Brazil.
Virgilio Souza E SilvaDepartment of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-900, Brazil.
Iara Monique MessiasInternational Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.
Alexcia Camila BraunInternational Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.ORCID 0000-0002-9028-2026
Anna Paula Carreta RuanoInternational Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.ORCID 0000-0001-7793-6032
Marcilei E C BuimFaculdade de Medicina de Marília, São Paulo 17519-030, Brazil.
Dirce Maria CarraroInternational Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.
Ludmilla Thomé Domingos ChinenInternational Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.
AC Camargo Hospital · BRFaculdade de Medicina de Marília · BR

Funding

Pronon 25000.055121/2015-12- Brazil
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) and/or circulating tumor microemboli (CTM) from non-small cell lung cancer (NSCLC) patients may be a non-invasive tool for prognosis, acting as liquid biopsy. CTCs interact with platelets through the transforming growth factor-β/transforming growth factor-β receptor type 1 (TGF-β/TGFβRI) forming clusters. CTCs also may express the Cluster of Differentiation 47 (CD47) protein, responsible for the inhibition of phagocytosis, the "don't eat me" signal to macrophages.

objectivesTo isolate, quantify and analyze CTCs/CTMs from metastatic NSCLC patients, identify TGFβRI/CD47 expression in CTCs/CTMs, and correlate with progression-free survival (PFS).

methodsBlood (10 mL) was collected at two time-points: T1 (before the beginning of any line of treatment; T2 (60 days after initial collection). CTCs were isolated using ISET

results45 patients were evaluated. CTCs were observed in 82.2% of patients at T1 (median: 1 CTC/mL; range: 0.33-11.33 CTCs/mL) and 94.5% at T2 (median: 1.33 CTC/mL; 0.33-9.67). CTMs were observed in 24.5% of patients and significantly associated with poor PFS (10 months vs. 17 months for those without clusters;

conclusionIn this study, we observed that CTC/CTM from NSCLC patients express the immune evasion markers TGFβRI/CD47. The presence of CTMs CD47+ is associated with poor PFS. This was the first study to investigate CD47 expression in CTCs/CTM of patients with NSCLC and its association with poor PFS.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplastic Cells, CirculatingBiomarkersBiomarkers, TumorCD47 AntigenHumansReceptor, Transforming Growth Factor-beta Type ITransforming Growth FactorsBiomarkersBiomarkers, TumorCD47 AntigenCD47 protein, humanReceptor, Transforming Growth Factor-beta Type ITransforming Growth FactorsCD47circulating tumor cellscirculating tumor microemboliliquid biopsylung cancernon-small cell lung cancer (NSCLC)

Identifiers

PMID37569332
PMCPMC10419161
OpenAlexW4385269473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.